Deutsche Bank initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on REGN. Citigroup reiterated a “buy” rating and set a $575.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, September 7th. Raymond James Financial reiterated an “outperform” rating and set a $566.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 6th. Morgan Stanley reiterated an “equal weight” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 23rd. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Finally, J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average price target of $467.84.

Regeneron Pharmaceuticals (REGN) traded up $0.40 during trading hours on Tuesday, reaching $381.72. 456,416 shares of the company’s stock were exchanged, compared to its average volume of 905,445. The stock has a market cap of $40,910.63, a price-to-earnings ratio of 32.97, a price-to-earnings-growth ratio of 1.50 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals has a 52 week low of $340.09 and a 52 week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.13 EPS. equities analysts predict that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current year.

In other Regeneron Pharmaceuticals news, Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the sale, the director now owns 11,000 shares of the company’s stock, valued at $4,950,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of REGN. Fieldpoint Private Securities LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $130,000. Sterling Investment Advisors Ltd. grew its position in Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 28 shares in the last quarter. FNY Partners Fund LP grew its position in Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 200 shares in the last quarter. IFP Advisors Inc grew its position in Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 96 shares in the last quarter. Finally, Vident Investment Advisory LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $200,000. 66.67% of the stock is owned by institutional investors.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/regeneron-pharmaceuticals-regn-now-covered-by-deutsche-bank/1760093.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.